These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 33015101)

  • 21. High angiopoietin-2 levels associate with arterial inflammation and long-term glucocorticoid requirement in polymyalgia rheumatica.
    van Sleen Y; Boots AMH; Abdulahad WH; Bijzet J; Sandovici M; van der Geest KSM; Brouwer E
    Rheumatology (Oxford); 2020 Jan; 59(1):176-184. PubMed ID: 31292652
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Inflammatory Markers are Quickly Improved by Tocilizumab in Early Polymyalgia Rheumatica and Might Predict Early Response to Interleukin-6 Blockade.
    Carvajal Alegria G; Cornec DYK; Renaudineau Y; Saraux A; Devauchelle-Pensec V
    Rheumatol Ther; 2021 Jun; 8(2):751-760. PubMed ID: 33745124
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [PHASIC CHANGES OF BONE MASS, BONE TURNOVER MARKERS, AND ESTROGEN LEVELS AT DIFFERENT TIME POINTS AFTER GLUCOCORTICOID INTERVENTION AND THEIR CORRELATION IN RATS].
    Ren H; Shen G; Jiang X; Liang D; Tang J; Cui J; Lin S; Zhuang H; Yang Z; Zhang S; Yao Z
    Zhongguo Xiu Fu Chong Jian Wai Ke Za Zhi; 2015 Mar; 29(3):307-14. PubMed ID: 26455196
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Glucocorticoid effects on adrenal steroids and cytokine responsiveness in polymyalgia rheumatica and elderly onset rheumatoid arthritis.
    Sulli A; Montecucco CM; Caporali R; Cavagna L; Montagna P; Capellino S; Fazzuoli L; Seriolo B; Alessandro C; Secchi ME; Cutolo M
    Ann N Y Acad Sci; 2006 Jun; 1069():307-14. PubMed ID: 16855158
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Contribution of the polymyalgia rheumatica activity score to glucocorticoid dosage adjustment in everyday practice.
    Cleuziou C; Binard A; De Bandt M; Berthelot JM; Saraux A
    J Rheumatol; 2012 Feb; 39(2):310-3. PubMed ID: 22174199
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Comparable Rates of Glucocorticoid-Associated Adverse Events in Patients With Polymyalgia Rheumatica and Comorbidities in the General Population.
    Shbeeb I; Challah D; Raheel S; Crowson CS; Matteson EL
    Arthritis Care Res (Hoboken); 2018 Apr; 70(4):643-647. PubMed ID: 28704600
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effects of strontium ranelate on bone mass and bone turnover in women with thalassemia major-related osteoporosis.
    Morabito N; Catalano A; Gaudio A; Morini E; Bruno LM; Basile G; Tsiantouli E; Bellone F; Agostino RM; Piraino B; La Rosa MA; Salpietro C; Lasco A
    J Bone Miner Metab; 2016 Sep; 34(5):540-6. PubMed ID: 26204844
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Naïve Inflammatory Proteome Profiles of Glucocorticoid Responsive Polymyalgia Rheumatica and Rheumatic Arthritis Patients-Links to Triggers and Proteomic Manifestations.
    Stensballe A; Andersen JS; Aboo C; Andersen AB; Ren J; Meyer MK; Lambertsen KL; Leutscher PDC
    J Pers Med; 2024 Apr; 14(5):. PubMed ID: 38793033
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Permanent Discontinuation of Glucocorticoids in Polymyalgia Rheumatica Is Uncommon but May Be Enhanced by Amino Bisphosphonates.
    Giollo A; Rossini M; Bettili F; Ghellere F; Fracassi E; Idolazzi L; Gatti D; Viapiana O
    J Rheumatol; 2019 Mar; 46(3):318-322. PubMed ID: 30385701
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Denosumab effects on bone density and turnover in postmenopausal women with low bone mass with or without previous treatment.
    Tsourdi E; Makras P; Rachner TD; Polyzos S; Rauner M; Mandanas S; Hofbauer LC; Anastasilakis AD
    Bone; 2019 Mar; 120():44-49. PubMed ID: 30292818
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Tocilizumab for polymyalgia rheumatica: report of two cases and review of the literature.
    Macchioni P; Boiardi L; Catanoso M; Pulsatelli L; Pipitone N; Meliconi R; Salvarani C
    Semin Arthritis Rheum; 2013 Aug; 43(1):113-8. PubMed ID: 23433960
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Assessing polymyalgia rheumatica activity when C-reactive protein is unavailable or uninterpretable.
    Devauchelle-Pensec V; Saraux L; Berthelot JM; De Bandt M; Cornec D; Guellec D; Marhadour T; Jousse-Joulin S; Gouillou M; Saraux A
    Rheumatology (Oxford); 2018 Apr; 57(4):666-670. PubMed ID: 29346621
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Adjuvant tamoxifen but not aromatase inhibitor therapy decreases serum levels of the Wnt inhibitor dickkopf-1 while not affecting sclerostin in breast cancer patients.
    Göbel A; Kuhlmann JD; Link T; Wimberger P; Browne AJ; Rauner M; Hofbauer LC; Rachner TD
    Breast Cancer Res Treat; 2017 Aug; 164(3):737-743. PubMed ID: 28526959
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Distinct effect of zoledronate and clodronate on circulating levels of DKK1 and sclerostin in women with postmenopausal osteoporosis.
    Gatti D; Viapiana O; Idolazzi L; Fracassi E; Ionescu C; Dartizio C; Troplini S; Kunnathully V; Adami S; Rossini M
    Bone; 2014 Oct; 67():189-92. PubMed ID: 25003812
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Increased extracellular water measured by bioimpedance analysis and increased serum levels of atrial natriuretic peptide in polymyalgia rheumatica patients : Signs of volume overload.
    Günther F; Ehrenstein B; Hartung W; Boschiero D; Fleck M; Straub RH
    Z Rheumatol; 2021 Mar; 80(2):140-148. PubMed ID: 32761369
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Efficacy of first-line tocilizumab therapy in early polymyalgia rheumatica: a prospective longitudinal study.
    Devauchelle-Pensec V; Berthelot JM; Cornec D; Renaudineau Y; Marhadour T; Jousse-Joulin S; Querellou S; Garrigues F; De Bandt M; Gouillou M; Saraux A
    Ann Rheum Dis; 2016 Aug; 75(8):1506-10. PubMed ID: 26929219
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Factors associated with serum soluble inhibitors of Wnt-β-catenin signaling (sclerostin and dickkopf-1) in patients undergoing peritoneal dialysis.
    Yamada S; Tsuruya K; Tokumoto M; Yoshida H; Ooboshi H; Kitazono T
    Nephrology (Carlton); 2015 Sep; 20(9):639-45. PubMed ID: 25974190
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Hypothalamic-pituitary-adrenal axis impairment in the pathogenesis of rheumatoid arthritis and polymyalgia rheumatica.
    Cutolo M; Foppiani L; Minuto F
    J Endocrinol Invest; 2002; 25(10 Suppl):19-23. PubMed ID: 12508908
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The effect of tocilizumab on bone mineral density, serum levels of Dickkopf-1 and bone remodeling markers in patients with rheumatoid arthritis.
    Briot K; Rouanet S; Schaeverbeke T; Etchepare F; Gaudin P; Perdriger A; Vray M; Steinberg G; Roux C
    Joint Bone Spine; 2015 Mar; 82(2):109-15. PubMed ID: 25557658
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Immediate fall of bone formation and transient increase of bone resorption in the course of high-dose, short-term glucocorticoid therapy in young patients with multiple sclerosis.
    Dovio A; Perazzolo L; Osella G; Ventura M; Termine A; Milano E; Bertolotto A; Angeli A
    J Clin Endocrinol Metab; 2004 Oct; 89(10):4923-8. PubMed ID: 15472186
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.